Emphysema Market Size, Share and Trends Analysis, Therapeutics Pipeline Outlook, and Epidemiology Insights 2032 | Key Companies – Mereo BioPharma, GlaxoSmithKline, United Therapeutics, and Others

April 26 05:05 2022
Emphysema Market Size, Share and Trends Analysis, Therapeutics Pipeline Outlook, and Epidemiology Insights 2032 | Key Companies - Mereo BioPharma, GlaxoSmithKline, United Therapeutics, and Others
Delveinsight Business Research LLP
DelveInsight’s “Emphysema Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Emphysema Market Size and Share in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Emphysema market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Emphysema Market

Emphysema: An Overview

Emphysema is one of the diseases that comprise COPD (chronic obstructive pulmonary disease). COPD is a group of lung diseases that make it hard to breathe and get worse over time. According to American Lung Association, Emphysema develops over time and involves the gradual damage of lung tissue, specifically the destruction of the alveoli (tiny air sacs).

Emphysema cannot be cured, however, many treatments are available to help manage symptoms. Bronchodilator medications relax the muscles, anti-inflammatory medication can reduce airway inflammation, and oxygen therapy can assist patients who need help breathing. In extreme situations, lung volume reduction surgery can relieve pressure by removing a portion of diseased lung tissue.

Emphysema Market Key Facts

  • The prevalence of emphysema in the United States is approximately 14 million, which includes 14% white male smokers and 3% white male nonsmokers. The prevalence is slightly less for white female smokers and African Americans (Pahal et al., 2020).

  • According to Pahal et al. (2020), smokers are more likely to present with Emphysema than non-smokers.

  • A rare hereditary autosomal recessive disease, alpha one antitrypsin deficiency, can also lead to emphysema and liver abnormalities. However, it only contributes to 1% to 2% of cases of COPD.

  • According to the Centers for Disease Control and Prevention, the number of adults who have ever been diagnosed with emphysema in the United States was around 3.8 million in 2016.

Emphysema Market

Emphysema Market Size is expected to increase during the forecast period owing to the rising cases in the 7MM and the launch of the emerging therapies. Better diagnostic services and understanding of the disease are also anticipated to boost the therapeutic market growth in the coming years.

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Emphysema market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Emphysema market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Emphysema Epidemiology

The epidemiology section covers insights into the historical and current Emphysema patient pool and forecasted trends for every seven major countries (7MM)  from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool, future trends, and assumptions undertaken.

Emphysema Epidemiology Segmentation

  • Total prevalent cases of Emphysema

  • Total diagnosed and treatable cases of Emphysema

  • Etiology-specific cases of Emphysema

  • Age-specific cases of Emphysema

Emphysema Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Emphysema market or expected to get launched during the study period. The analysis covers Emphysema market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Emphysema Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/emphysema-market

Emphysema Therapeutics Analysis

Worldwide some of the key players are diligently involved in the development of therapies for the Emphysema. Some of the therapies are in the advanced stages expected to launch in the coming years. 

Some of the key companies in the Emphysema Market include:

  • Mereo BioPharma

  • GlaxoSmithKline

  • United Therapeutics

And many others.

Emphysema Therapies covered in the report include:

  • Alvelestat

  • Tyvaso Treprostinil 

  • Belimumab 

And many more.

Get More Detailed Insights Into the Emerging Therapies & Key Companies –  https://www.delveinsight.com/sample-request/emphysema-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Emphysema Competitive Intelligence Analysis

4. Emphysema Market Overview at a Glance

5. Emphysema Disease Background and Overview

6. Emphysema Patient Journey

7. Emphysema Epidemiology and Patient Population

8. Emphysema Treatment Algorithm, Current Treatment, and Medical Practices

9. Emphysema Unmet Needs

10. Key Endpoints of Emphysema Treatment

11. Emphysema Marketed Products

12. Emphysema Emerging Therapies

13. Emphysema Seven Major Market Analysis

14. Attribute Analysis

15. Emphysema Market Outlook (7 major markets)

16. Emphysema Access and Reimbursement Overview

17. KOL Views on the Emphysema Market.

18. Emphysema Market Drivers

19. Emphysema Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/emphysema-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Other Latest Reports By DelveInsight

Pars Plantis Market

DelveInsight’s “Pars Plantis Market” report delivers an in-depth understanding of the historical and forecasted epidemiology, the Pars Plantis market size, and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan) as well as the emerging therapies and key companies in the therapeutic domain.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/